Company / Net Income
Foghorn Therapeutics Inc. Net Income History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$86.6M
FY2025
5-year range
-$108.9M / -$68.8M
FY2021-FY2025
Trend
+12.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from -$109M to -$87M over the past 2 years.
Based on SEC 10-K filings.
-$87M in FY2025.
Improved from -$109M to -$87M over the past 2 years.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, net income increased 12.0% year-over-year.
- Peak net income was recorded in FY2020.
- Lowest net income in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score -1.20 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$86.6M | +12.0% |
| FY2024 | -$98.4M | +9.6% |
| FY2023 | -$108.9M | -7.5% |
| FY2022 | -$101.3M | -47.3% |
| FY2021 | -$68.8M | -34.6% |
| FY2020 | -$51.1M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026